Skip to main content

Table 1 Baseline characteristics for both cohorts

From: A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients

Characteristics

Training cohort (n = 84)

Validation cohort (n = 36)

apCR (n = 37)

non-apCR (n = 47)

P

apCR (n = 16)

non-apCR (n = 20)

p

Age (years)

50.5 ± 8.7

50.7 ± 10.9

0.928

49.8 ± 11.5

53.3 ± 9.6

0.329

Menopausal (%)

  

0.679

  

1.000

 Premenopausal

18 (48.6)

25 (53.2)

 

7 (43.8)

8 (40.0)

 

 Postmenopausal

19 (51.4)

22 (46.8)

 

9 (56.2)

12 (60.0)

 

ER status (%)

  

0.001

  

0.191

 Positive

13 (35.1)

33 (70.2)

 

5 (31.2)

11 (55.0)

 

 Negative

24 (64.9)

14 (29.8)

 

11 (68.8)

9 (45.0)

 

PR status (%)

  

0.022

  

0.500

 Positive

16 (43.2)

32 (68.1)

 

8 (50.0)

13 (65.0)

 

 Negative

21 (56.8)

15 (31.9)

 

8 (50.0)

7 (35.0)

 

HER2 status (%)

  

0.002

  

0.023

 Positive

21 (56.8)

11 (23.4)

 

12 (75.0)

7 (35.0)

 

 Negative

16 (43.2)

36 (76.6)

 

4 (25.0)

13 (65.0)

 

Ki-67 status (%)

  

0.659

  

0.764

  ≤ 20%

5 (13.5)

8 (17.0)

 

3 (18.8)

3 (15.0)

 

 > 20%

32 (86.5)

39 (83.0)

 

13 (81.2)

17 (85.0)

 

Molecular subtypes (%)

  

0.005

  

0.073

 Luminal A

1 (2.7)

5 (10.6)

 

0 (0.0)

1 (5.0)

 

 Luminal B

17 (45.9)

29 (61.7)

 

8 (50.0)

13 (65.0)

 

 HER2 enriched

12 (32.4)

2 (4.3)

 

6 (37.5)

1 (5.0)

 

 TN

7 (18.9)

11 (23.4)

 

2 (12.5)

5 (25.0)

 

Clinical T stage (%)

  

0.993

  

0.525

 T1

6 (16.2)

8 (17.0)

 

2 (12.5)

5 (25.0)

 

 T2

15 (40.5)

20 (42.6)

 

10 (62.5)

8 (40.0)

 

 T3

8 (21.6)

9 (19.1)

 

1 (6.2)

3 (15.0)

 

 T4

8 (21.6)

10 (21.3)

 

3 (18.8)

4 (20.0)

 

Clinical N stage (%)

  

0.317

  

0.273

 N1

26 (70.3)

32 (68.1)

 

14 (87.5)

12 (60.0)

 

 N2

9 (24.3)

8 (17.0)

 

1 (6.2)

4 (20.0)

 

 N3

2 (5.4)

7 (14.9)

 

1 (6.2)

4 (20.0)

 

Pre-LD (mm)

17.2 ± 6.9

18.3 ± 5.8

0.456

16.2 ± 4.9

18.9 ± 6.5

0.183

1st-LD (mm)

12.9 ± 5.2

14.5 ± 5.2

0.171

12.4 ± 4.7

14.8 ± 4.1

0.108

Pre-SD (mm)

12.9 ± 3.6

14.1 ± 4.6

0.184

12.8 ± 3.5

13.6 ± 4.1

0.547

1st-SD (mm)

9.7 ± 3.3

11.1 ± 4.6

0.130

9.4 ± 3.9

10.6 ± 2.9

0.294

Delta-LD (mm)

4.3 ± 2.5

3.8 ± 3.3

0.418

3.8 ± 2.4

4.0 ± 4.5

0.851

Delta-SD (mm)

3.2 ± 1.3

3.0 ± 2.8

0.769

3.4 ± 2.1

3.0 ± 3.4

0.665

Breast pCR (%)

      

 Yes

17 (45.9)

5 (10.6)

< 0.001

13 (81.2)

2 (10.0)

< 0.001

 No

20 (54.1)

42 (89.4)

 

3 (18.8)

18 (90.0)

 
  1. Age is presented as mean ± SD, and others shown as proportions (percentages)
  2. ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2, TN Triple negative, apCR Axillary pathologic complete response, pre- pretreatment, 1st One cycle, LD Long diameter, SD Short diameter, pCR Pathologic complete response
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us